Treatment of multiple sclerosis

Annals of Indian Academy of Neurology

Volumn 14, Issue SUPPL. 1, 2011, Pages

  Pandit, Lekha ^a   Murthy, J M K ^b  

^a NITTE UNIVERSITY   (India)

^b CARE HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; AZATHIOPRINE; BACLOFEN; BETA1A INTERFERON; BOTULINUM TOXIN; CARBAMAZEPINE; CLONAZEPAM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIAZEPAM; DONEPEZIL; GABAPENTIN; GLATIRAMER; INTERFERON BETA SERINE; LAMOTRIGINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MODAFINIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PLACEBO; PREDNISOLONE; PREGABALIN; PROPRANOLOL; STEROID; TIZANIDINE; TOPIRAMATE; UNINDEXED DRUG;

ARTICLE; CARDIOMYOPATHY; CEREBELLA TREMOR; CEREBELLAR TREMOR; CLINICAL FEATURE; COGNITIVE DEFECT; DISEASE COURSE; DRUG MECHANISM; DRUG MEGADOSE; FATIGUE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFERTILITY; INFLUENZA; INJECTION SITE REACTION; INTENTION TREMOR; LEUKEMIA; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHADENOPATHY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PAIN; PALLIATIVE THERAPY; PAROXYSMAL SYMPTOM; PAROXYSMAL TREMOR; PEPTIC ULCER; PREGNANCY; PREVALENCE; RELAPSE; SINGLE DRUG DOSE; SPASTICITY; THYROID DISEASE; TREMOR; URTICARIA;

EID: 79960947308     PISSN: 09722327     EISSN: 19983549     Source Type: Journal    
DOI: 10.4103/0972-2327.83094     Document Type: Article

References (20)

1. Weinshenker BG, Bass B, Rice PA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of Multiple Sclerosis: A geographically based study Clinical course and disability. Brain 1989;112:133-46. (Pubitemid 19056478)
2. Amato MP, De Stefano N. Longitudinal follow-up of benign Multiple Sclerosis at 20 years. Neurology 2007;69:938-9.
3. McDonald WI, Compston A, Edan G. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-7.
4. Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: Possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 2001;117:1-8. (Pubitemid 32595488)
5. Beck RW. The optic neuritis treatment trial: Three-year follow-up results. Arch Ophthalmol 1995;113:136-7.
6. Tremlett HL, Luscombe DK, Wiles CM. Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. J Neurol Neurosurg Psychiatry 1998;65:362-5. (Pubitemid 28408252)
7. Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: A comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993;56:1219-20. (Pubitemid 23323664)
8. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58;169-78. (Pubitemid 34086933)
9. Goodin DS. Disease-modifying therapy in multiple sclerosis: Update and clinical implications. Neurology 2008;71:S8-S13.
10. Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, et al. Long-term subcutaneous interferon beta- 1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-53. (Pubitemid 44454583)
11. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001;56:702-8. (Pubitemid 32240087)
12. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-8. (Pubitemid 27090928)
13. Edan G, Morrissey S, Le Page E. Rationale for the use of mitoxantrone in multiple sclerosis. J Neurol Science 2004;223:35-9. (Pubitemid 38903259)
14. Millefi orini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-9. (Pubitemid 27099852)
15. Ellis R, Boggild M. Therapy related acute leukemia with Mitoxantrone: What is the risk and can we minimize it ? Mult Scler 2009;15:505-8.
16. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, et al. The incidence and signifi cance of antinatalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology 2007;69:1391-403. (Pubitemid 47511460)
17. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74. (Pubitemid 41132341)
18. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998;339:285-91. (Pubitemid 28366416)
19. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically defi nite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9. (Pubitemid 44563835)
20. Henze T, Riekmann P, Toyka KV. Symptomatic Treatment of Multiple Sclerosis-Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol 2006;56:78-105. (Pubitemid 44492163)